Cargando…

Baroreflex activation therapy reduces frequency and duration of hypertension-related hospitalizations in patients with resistant hypertension

PURPOSE: Baroreflex activation therapy (BAT) has been shown to lower blood pressure in patients with resistant hypertension. The purpose of this study was to analyze whether this translates into a reduction of more relevant clinical endpoints. METHODS: Patients with resistant hypertension were treat...

Descripción completa

Detalles Bibliográficos
Autores principales: Halbach, Marcel, Grothaus, David, Hoffmann, Fabian, Madershahian, Navid, Kuhr, Kathrin, Reuter, Hannes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8302539/
https://www.ncbi.nlm.nih.gov/pubmed/32052254
http://dx.doi.org/10.1007/s10286-020-00670-9
_version_ 1783726900259061760
author Halbach, Marcel
Grothaus, David
Hoffmann, Fabian
Madershahian, Navid
Kuhr, Kathrin
Reuter, Hannes
author_facet Halbach, Marcel
Grothaus, David
Hoffmann, Fabian
Madershahian, Navid
Kuhr, Kathrin
Reuter, Hannes
author_sort Halbach, Marcel
collection PubMed
description PURPOSE: Baroreflex activation therapy (BAT) has been shown to lower blood pressure in patients with resistant hypertension. The purpose of this study was to analyze whether this translates into a reduction of more relevant clinical endpoints. METHODS: Patients with resistant hypertension were treated with the second-generation BAT system. Records on hospitalization (dates of admission and discharge, main diagnosis) were obtained from medical insurance companies. RESULTS: Records on hospitalization were available for a period of 1 year before BAT in two patients and 2 years in 22 patients. The total number of hospitalizations per patient was 3.3 ± 3.5/year before BAT and 2.2 ± 2.7/year after BAT (p = 0.03). Hospitalizations related to hypertension were significantly decreased from 1.5 ± 1.6/year before BAT to 0.5 ± 0.9/year after BAT (p < 0.01). The cumulative duration of hypertension-related hospital stays was significantly reduced from 8.0 ± 8.7 days/year before BAT to 1.8 ± 4.8 days/year after BAT (p < 0.01). Office cuff blood pressure was 183 ± 27 mmHg over 102 ± 17 mmHg under 6.6 ± 2.0 antihypertensive drugs before BAT and 157 ± 32 mmHg over 91 ± 20 mmHg (both p < 0.01) under 5.9 ± 1.9 antihypertensive drugs (p = 0.09 for number of drugs) at latest follow-up. Daytime ambulatory blood pressure was 164 ± 21 mmHg over 91 ± 14 mmHg before BAT and 153 ± 21 mmHg (p = 0.03) over 89 ± 15 mmHg (p = 0.56) at latest follow-up. Heart rate was 75 ± 16 bpm before BAT and 72 ± 12 bpm at latest follow-up (p = 0.35). CONCLUSIONS: Rate and duration of hypertension-related hospitalizations in patients with severe resistant hypertension were lowered after BAT. Whether the response is mediated through improvements in blood pressure control requires further studies. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s10286-020-00670-9) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-8302539
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-83025392021-07-27 Baroreflex activation therapy reduces frequency and duration of hypertension-related hospitalizations in patients with resistant hypertension Halbach, Marcel Grothaus, David Hoffmann, Fabian Madershahian, Navid Kuhr, Kathrin Reuter, Hannes Clin Auton Res Research Article PURPOSE: Baroreflex activation therapy (BAT) has been shown to lower blood pressure in patients with resistant hypertension. The purpose of this study was to analyze whether this translates into a reduction of more relevant clinical endpoints. METHODS: Patients with resistant hypertension were treated with the second-generation BAT system. Records on hospitalization (dates of admission and discharge, main diagnosis) were obtained from medical insurance companies. RESULTS: Records on hospitalization were available for a period of 1 year before BAT in two patients and 2 years in 22 patients. The total number of hospitalizations per patient was 3.3 ± 3.5/year before BAT and 2.2 ± 2.7/year after BAT (p = 0.03). Hospitalizations related to hypertension were significantly decreased from 1.5 ± 1.6/year before BAT to 0.5 ± 0.9/year after BAT (p < 0.01). The cumulative duration of hypertension-related hospital stays was significantly reduced from 8.0 ± 8.7 days/year before BAT to 1.8 ± 4.8 days/year after BAT (p < 0.01). Office cuff blood pressure was 183 ± 27 mmHg over 102 ± 17 mmHg under 6.6 ± 2.0 antihypertensive drugs before BAT and 157 ± 32 mmHg over 91 ± 20 mmHg (both p < 0.01) under 5.9 ± 1.9 antihypertensive drugs (p = 0.09 for number of drugs) at latest follow-up. Daytime ambulatory blood pressure was 164 ± 21 mmHg over 91 ± 14 mmHg before BAT and 153 ± 21 mmHg (p = 0.03) over 89 ± 15 mmHg (p = 0.56) at latest follow-up. Heart rate was 75 ± 16 bpm before BAT and 72 ± 12 bpm at latest follow-up (p = 0.35). CONCLUSIONS: Rate and duration of hypertension-related hospitalizations in patients with severe resistant hypertension were lowered after BAT. Whether the response is mediated through improvements in blood pressure control requires further studies. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s10286-020-00670-9) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2020-02-12 2020 /pmc/articles/PMC8302539/ /pubmed/32052254 http://dx.doi.org/10.1007/s10286-020-00670-9 Text en © The Author(s) 2020, corrected publication 2021 https://creativecommons.org/licenses/by/4.0/ Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research Article
Halbach, Marcel
Grothaus, David
Hoffmann, Fabian
Madershahian, Navid
Kuhr, Kathrin
Reuter, Hannes
Baroreflex activation therapy reduces frequency and duration of hypertension-related hospitalizations in patients with resistant hypertension
title Baroreflex activation therapy reduces frequency and duration of hypertension-related hospitalizations in patients with resistant hypertension
title_full Baroreflex activation therapy reduces frequency and duration of hypertension-related hospitalizations in patients with resistant hypertension
title_fullStr Baroreflex activation therapy reduces frequency and duration of hypertension-related hospitalizations in patients with resistant hypertension
title_full_unstemmed Baroreflex activation therapy reduces frequency and duration of hypertension-related hospitalizations in patients with resistant hypertension
title_short Baroreflex activation therapy reduces frequency and duration of hypertension-related hospitalizations in patients with resistant hypertension
title_sort baroreflex activation therapy reduces frequency and duration of hypertension-related hospitalizations in patients with resistant hypertension
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8302539/
https://www.ncbi.nlm.nih.gov/pubmed/32052254
http://dx.doi.org/10.1007/s10286-020-00670-9
work_keys_str_mv AT halbachmarcel baroreflexactivationtherapyreducesfrequencyanddurationofhypertensionrelatedhospitalizationsinpatientswithresistanthypertension
AT grothausdavid baroreflexactivationtherapyreducesfrequencyanddurationofhypertensionrelatedhospitalizationsinpatientswithresistanthypertension
AT hoffmannfabian baroreflexactivationtherapyreducesfrequencyanddurationofhypertensionrelatedhospitalizationsinpatientswithresistanthypertension
AT madershahiannavid baroreflexactivationtherapyreducesfrequencyanddurationofhypertensionrelatedhospitalizationsinpatientswithresistanthypertension
AT kuhrkathrin baroreflexactivationtherapyreducesfrequencyanddurationofhypertensionrelatedhospitalizationsinpatientswithresistanthypertension
AT reuterhannes baroreflexactivationtherapyreducesfrequencyanddurationofhypertensionrelatedhospitalizationsinpatientswithresistanthypertension